NEW YORK, NY / ACCESSWIRE / August 22, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc.(“Sarepta” or the “Company”) (NASDAQ:SRPT). Investors who purchased Sareptas ecuritiesare encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/srpt.
The investigation concerns whether Sareptaand certain of its officers and/or directors have violated federal securities laws.
On August 19, 2019, Sarepta announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food & Drug Administration regarding the Company’s New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that “[t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides.” On this news, Sarepta’s stock price fell sharply, damaging investors.
If you are aware of any facts relating to this investigation, or purchased Sarepta shares,you can assist this investigation by visiting the firm’s site: www.bgandg.com/srpt. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC